Hofseth Biocare ASA: HBC IMMUNOLOGY COMPLETES IN VIVO DRUG LEAD STUDIES FOR PROSTATE CANCER TREATMENT

GlobeNewswire10-08

Ålesund, Norway, 8 October 2024. HBC Immunology (HBCI) is pleased to announce the successful completion of its prostate cancer treatment xenograft studies with its lead peptide FT-002a in a novel oral...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2473251418?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/e1dUCnC7i3aVR.ZDruqYhg--~B/aD03NjM7dz0yNTYxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/4e575d7fd4f2115cf22186a9906bc5ab","is_english":true,"pubTime":"2024-10-08 14:45","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2473251418","market":"us","top_or_hot":-1,"title":"Hofseth Biocare ASA: HBC IMMUNOLOGY COMPLETES IN VIVO DRUG LEAD STUDIES FOR PROSTATE CANCER TREATMENT","media":"GlobeNewswire","content":"<div>\n<p>Ålesund, Norway, 8 October 2024.\nHBC Immunology (HBCI) is pleased to announce the successful completion of its prostate cancer treatment xenograft studies with its lead peptide FT-002a in a novel oral...</p>\n\n<a href=\"https://finance.yahoo.com/news/hofseth-biocare-asa-hbc-immunology-064500028.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hofseth Biocare ASA: HBC IMMUNOLOGY COMPLETES IN VIVO DRUG LEAD STUDIES FOR PROSTATE CANCER TREATMENT</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHofseth Biocare ASA: HBC IMMUNOLOGY COMPLETES IN VIVO DRUG LEAD STUDIES FOR PROSTATE CANCER TREATMENT\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-08 14:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/hofseth-biocare-asa-hbc-immunology-064500028.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ålesund, Norway, 8 October 2024.\nHBC Immunology (HBCI) is pleased to announce the successful completion of its prostate cancer treatment xenograft studies with its lead peptide FT-002a in a novel oral...</p>\n\n<a href=\"https://finance.yahoo.com/news/hofseth-biocare-asa-hbc-immunology-064500028.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4198","symbol_name":"医疗保健用品","start_time":0,"source_url":"https://finance.yahoo.com/news/hofseth-biocare-asa-hbc-immunology-064500028.html","article_id":"2473251418","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/e1dUCnC7i3aVR.ZDruqYhg--~B/aD03NjM7dz0yNTYxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/4e575d7fd4f2115cf22186a9906bc5ab"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2473251418","pubTimestamp":1728369900,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"HBC Immunology  is pleased to announce the successful completion of its prostate cancer treatment xenograft studies with its lead peptide FT-002a in a novel oral formulation in combination with standard of care hormonal-targeting therapy. Oral FT-002a significantly augmented the anti-tumour activity of enzalutamide  the market-leading androgen receptor inhibitor, in models of indolent and aggressive prostate cancers.Research is ongoing to identify the individual elements within its ingredients that modulate inflammation and the immune response with pre-clinical studies ongoing in multiple clinics and university research labs. Lead clinical and pre-clinical candidates are focused on developing an oral treatment for inflammatory disease driven by eosinophils . Clinical trial work with full-spectrum omega salmon oil is ongoing to improve respiratory health in individuals with allergic asthma and in urban populations exposed to significant levels of pollution and has already shown benefici","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4198":"医疗保健用品","LEAD":"Siren DIVCON Leaders Dividend ETF","MAR":"万豪酒店","ASA":"ASA百慕大基金","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","FOR":"福里斯特","BK4142":"酒店、度假村与豪华游轮","BK4139":"生物科技","HOFBF":"Hofseth Biocare ASA","DRUG":"Bright Minds Biosciences Inc","BK4024":"房地产开发","BK4585":"ETF&股票定投概念","VIVO":"美鼎生物","BK4588":"碎股"},"translate_title":"Hofseth Biocare ASA：HBC IMMUNOLOGY完成前列腺癌治疗体内药物先导研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASA":1,"DRUG":1,"FOR":1,"HOFBF":1,"LEAD":1,"MAR":1,"VIVO":1},"content_text":"Ålesund, Norway, 8 October 2024.\nHBC Immunology (HBCI) is pleased to announce the successful completion of its prostate cancer treatment xenograft studies with its lead peptide FT-002a in a novel oral formulation in combination with standard of care hormonal-targeting therapy. Oral FT-002a significantly augmented the anti-tumour activity of enzalutamide (Xtandi®) the market-leading androgen receptor inhibitor, in models of indolent and aggressive prostate cancers.\nProstate cancer remains the most diagnosed cancer in men. Whilst most cases do not shorten life expectancy, advanced prostate cancer remains incurable. Hormone therapy remains the cornerstone of treatment; however, tumours eventually find ways of overcoming treatment and start to grow and spread. Co-therapies that can reinvigorate cancer treatments can provide vital clinical avenues to enhance tumour cell sensitivity, as well as reversing resistance to standard cancer therapies.\nDr Bomi Framroze, Chief Executive Officer of HBCI explains: \"The ability of cancer to hack the iron metabolism pathways is an important driver of tumour growth and spread, and a means by which cancers can overcome the effects of treatment. Our lead peptide candidate, FT-002a, holds exciting potential to enhance the effectiveness of cancer therapy and improve the health and wellness of cancer patients.\"\nHigher levels of iron are needed by cancer cells to support growth and spread. In addition to elevated levels of tumour regression, FT-002a demonstrated a significant decrease in biomarkers of free iron in prostate cancer tumour cells, validating the proposed mode of action. \nThe combination of these promising results with the inherent safety profile of peptidyl drugs means HBCI is well positioned to make an IND submission for its oral co-therapy for prostate cancer treatment in Q4 2025.\nFor further information on HBC, please contact: Dr Crawford Currie, Head of Medical R&D Tel: +44 7968 195 497cc@hofsethbiocare.com\nAbout HBC:HBC is a Norwegian human and pet health ingredient supplier and an incubator for new pharmaceutical drug leads, which are then developed by HBCI to enable the clinical development of novel therapies. To date, the FT peptides, targeting cancer, and MA-022, for asthma, have been transferred to HBCI for ongoing R&D work. HBC retains 70% ownership of HBCI.\nResearch is ongoing to identify the individual elements within its ingredients that modulate inflammation and the immune response with pre-clinical studies ongoing in multiple clinics and university research labs. Lead clinical and pre-clinical candidates are focused on developing an oral treatment for inflammatory disease driven by eosinophils (a type of white blood cell). Clinical trial work with full-spectrum omega salmon oil is ongoing to improve respiratory health in individuals with allergic asthma and in urban populations exposed to significant levels of pollution and has already shown beneficial effects on COVID recovery.\nOther leads are focused on the protection of the Gastro-Intestinal (GI) system against inflammation (including ulcerative colitis and the orphan condition necrotizing enterocolitis) and the use of a special formula of soluble protein hydrolysate (SPH, also known as ProGo®) as a Medical Food to help treat IBD and Iron Deficiency Anemia.\nThe company is founded on the core values of sustainability, optimal utilization of natural resources and full traceability. Through an innovative hydrolysis technology, HBC can preserve the quality of the lipids, proteins and calcium from fresh salmon off-cuts. HBC's headquarters are in Ålesund, Norway with branches in Oslo, London, Zürich, New Jersey and Palo Alto.\nHBC is listed on Oslo Børs with ticker \"HBC\". https://hofsethbiocare.com\nThis information is considered to be inside information pursuant to the EU Market Abuse Regulation (MAR) and is subject to the disclosure requirements pursuant to MAR article 17 and section 5-12 of the Norwegian Securities Trading Act.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2473251418"}